{{Drugbox
| IUPAC_name               = [5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1''H''-chromeno[4,3-c]pyridin-10-yl] 2-methyl-4-(2-methylpiperidin-1-yl)butanoate
| image                    = Menabitan.svg
| CAS_number               = 83784-21-8
| CAS_supplemental         = <br />{{CAS|58019-50-4}} ([[hydrochloride|HCl]])
| ATC_prefix               = None
| ATC_suffix               = 
| PubChem                  = 189877
| ChemSpiderID             = 164903
| C=37 | H=56 | N=2 | O=3
| molecular_weight         = 576.85214 g/mol
| smiles                   = CCCCCC(C)C(C)C1=CC2=C(C3=C(CCN(C3)CC#C)C(O2)(C)C)C(=C1)OC(=O)C(C)CCN4CCCCC4C
| StdInChI = 1S/C37H56N2O3/c1-9-11-12-15-26(3)29(6)30-23-33(41-36(40)27(4)17-22-39-20-14-13-16-28(39)5)35-31-25-38(19-10-2)21-18-32(31)37(7,8)42-34(35)24-30/h2,23-24,26-29H,9,11-22,25H2,1,3-8H3
| StdInChIKey = ZWLPJYVIMWAEDC-UHFFFAOYSA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_US                 = Analogue 
| legal_US_comment         = (Schedule I)
| routes_of_administration = 
}}

'''Menabitan''' ([[International Nonproprietary Name|INN]]; '''SP-204'''), or '''menabitan hydrochloride''' ([[United States Adopted Name|USAN]]), is a [[Chemical synthesis|synthetic]] [[drug]] which acts as a [[potency (pharmacology)|potent]] [[cannabinoid receptor]] [[agonist]].<ref name="pmid402656">{{cite journal | author = Green K, Kim K | title = Acute dose response of intraocular pressure to topical and oral cannabinoids | journal = Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) | volume = 154 | issue = 2 | pages = 228–31 |date=February 1977 | pmid = 402656 | doi = 10.3181/00379727-154-39643| url = }}</ref><ref name="isbn978-0-412-46630-4">{{cite book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | page = 1271 | isbn = 978-0-412-46630-4 | oclc = | doi = | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1271}}</ref> It is closely related to [[natural product|natural]] [[cannabinoid]]s of the [[tetrahydrocannabinol]] (THC) group, differing mainly by its longer and branched [[side chain]], and the replacement of the 9-position carbon with a  nitrogen.<ref name="pmid402656" /> It was studied as an [[analgesic]] in the 1970s and was found to possess [[antinociceptive]] effects in both humans and animals but was never marketed.<ref name="pmid402656" /><ref name="pmid2830539">{{cite journal | author = Reggio PH | title = Molecular determinants for cannabinoid activity: refinement of a molecular reactivity template | journal = NIDA Research Monograph | volume = 79 | issue = | pages = 82–95 | year = 1987 | pmid = 2830539 | doi = | url = }}</ref><ref name="Nahas1999">{{cite book | author = Gabriel G. Nahas | title = Marihuana and Medicine | url = https://books.google.com/books?id=eWrbKBQ5j7gC&pg=PA46 | accessdate = 9 May 2012 | date = 5 April 1999 | publisher = Humana Press | isbn = 978-0-89603-593-5 | page = 46}}</ref>

Due to its structural similarity to the schedule I/III drug THC it can be treated as a schedule I drug within the United States legal system under the [[Federal Analogue Act]].

== See also ==
* [[A-40174]] (SP-1)
* [[Dimethylheptylpyran]]

== References ==
{{Reflist}}

{{Analgesics}}
{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Analgesics]]
[[Category:Butyrates]]
[[Category:Cannabinoids]]
[[Category:Piperidines]]
[[Category:Pyridines]]
[[Category:Chromenes]]


{{cannabinoid-stub}}